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Familial primary localized cutaneous amyloidosis (FPLCA) is an autosomal-dominant disorder associated with chronic skin itching and
deposition of epidermal keratin ﬁlament-associated amyloid material in the dermis. FPLCA has been mapped to 5p13.1–q11.2, and by
candidate gene analysis, we identiﬁed missense mutations in the OSMR gene, encoding oncostatin M-speciﬁc receptor b (OSMRb), in
three families. OSMRb is a component of the oncostatin M (OSM) type II receptor and the interleukin (IL)-31 receptor, and cultured
FPLCA keratinocytes showed reduced activation of Jak/STAT, MAPK, and PI3K/Akt pathways after OSM or IL-31 cytokine stimulation.
The pathogenic amino acid substitutions are located within the extracellular ﬁbronectin type III-like (FNIII) domains, regions critical
for receptor dimerization and function. OSM and IL-31 signaling have been implicated in keratinocyte cell proliferation, differentiation,
apoptosis, and inﬂammation, but our OSMR data in individuals with FPLCA represent the ﬁrst human germline mutations in this
cytokine receptor complex and provide new insight into mechanisms of skin itching.Introduction
One of the most common and least well understood symp-
toms in dermatology is itchy skin (also known as pruri-
tus).1 To date, relatively little is known about the key itch
mediators, receptors, and pathways, and consequently
effective therapies for alleviating symptoms of itch are
limited. One particular pruritic skin disorder often seen
by dermatologists is primary localized cutaneous amyloid-
osis (PLCA [MIM 105250]). This condition usually presents
with itching (especially on the lower legs) and visible
changes of skin hyperpigmentation and thickening (li-
cheniﬁcation) that may be exacerbated by chronic scratch-
ing and rubbing.2 Despite its name, PLCA is not associated
with other systemic forms of amyloidosis: the skin in PLCA
shows ﬁbrillary degeneration of basal keratinocytes with
increased apoptosis, disruption of dermal unmyelinated
nerve ﬁbers, and accumulation of melanosomes in der-
mal macrophages and Schwann cells.3–5 The ‘‘amyloid’’
in PLCA probably reﬂects a combination of degenerate ker-
atin ﬁlaments, serum amyloid P component, and second-
ary deposition of immunoglobulins. Nevertheless, PLCA
has been reported to coexist with several other clinical
disorders such as connective tissue diseases (e.g., systemic
lupus erythematosus, rheumatoid arthritis, systemic
sclerosis, scleroderma, primary biliary cirrhosis, and
dermatomyositis) as well as multiple endocrine neoplasia
type 2A (MEN2A [MIM 171400]).2 PLCA in some individ-Thuals with MEN2A has been associated with speciﬁc amino
acid substitutions in the RET proto-oncogene (especially
involving codon 634), but no RET gene pathology has
been disclosed in cases of PLCA in the absence of
MEN2A.6–9 Most clinical cases of PLCA are sporadic but
the disorder is more common in certain parts of the world,
including South America and Southeast Asia, where up to
10% of cases may be familial (autosomal dominant). Ge-
netic heterogeneity is suspected, however, because recent
genome-wide scans for familial PLCA (FPLCA) in Taiwan
have suggested genetic linkage to 1q23 or 5p13.1-q11.2
or perhaps other undisclosed loci, with the most signiﬁ-
cant LOD scores for the disease locus on chromosome
5.10,11 Identifying the gene for FPLCA, therefore, might
be expected to give signiﬁcant new insight into certain
pathophysiological mechanisms underlying skin itching,
inﬂammation, and keratinocyte apoptosis.
In this study, we mapped a large Brazilian family with
FPLCA to 5p13.1-q11.2 and performed candidate gene
analysis by sequencing genomic DNA. We found a mis-
sense mutation in the OSMR gene, which encodes the
oncostatin M receptor b (OSMRb), in all the affected indi-
viduals of the Brazilian FPLCA family. Further investiga-
tion in two other white families with FPLCA (from the
United Kingdom and South Africa) also disclosed muta-
tions in OSMR. Abnormalities in OSMRb signaling after
stimulation with the ligands OSM and IL-31 were demon-
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Table 1. Results of Microsatellite Analysis on FPLCA Locus 5p13.1–q11.2
Recombination Fractions
Locus Z Max q 0 0.01 0.05 0.1 0.2 0.3 0.4
D5S426 2.650448 0 2.65045 2.60028 2.396885 2.13661 1.597563 1.041051 0.488485
D5S2021 3.475509 0.05 N 3.087335 3.475509 3.371219 2.800568 2.015219 1.079287
D5S418 4.801343 0 4.80134 4.720222 4.387974 3.954395 3.021799 1.999922 0.927309
D5S1969 3.474038 0 3.47404 3.414591 3.171226 2.854256 2.178197 1.455041 0.714624
D5S407 1.352818 0.09 N 0.776918 1.288535 1.350272 1.156844 0.821459 0.426546genemutations being responsible for FPLCA as well as gen-
erating intriguing new data onmechanisms of pruritus and
keratinocyte apoptosis in human skin.
Material and Methods
DNA Samples, Microsatellite Analysis,
and Sequencing
After Ethical Committee approval and in compliance with the
Helsinki Accord, and after obtaining informed consent from all
subjects, genomic DNA was extracted from peripheral blood sam-
ples obtained from three FPLCA families (I-1; II-3 to 6; III-1, 3 to 6,
8 to 17; IV-2 to 4, 6 to 9 of Family 1; three affected individuals from
Family 2, and two affected individuals from Family 3). DNA was
ampliﬁed with ﬁve primer sets for microsatellite markers located
between 5p13.2 and 5q11.2 (Table 1). These primers were ob-74 The American Journal of Human Genetics 82, 73–80, January 200tained from the ABI PRISM Linkage Mapping Set Version 2.5
(Applied Biosystems). The PCR products were analyzed on an
ABI 310 DNA sequencer with Genescan 2.1 and Genotyper 2.0
software (Applied Biosystems). Two-point LOD scores were com-
puted by the MLINK algorithm of LINKAGE version 5.1 under
the assumptions of a mutant allele frequency of 0.00001 and
100% penetrance. Candidate gene analysis was then performed
(see Results for rationale of gene selection). For sequencing, DNA
samples were ampliﬁed with primers sited in introns ﬂanking in-
dividual exons of the OSMR gene (details available on request)
and IL31RA, IL6ST, and LIFR genes (primer details available on re-
quest). PCR products were sequenced with ABI BigDye Terminator
reagents (Applied Biosystems) in an ABI 310 sequencer.
RT-PCR
mRNA was extracted from skin biopsy specimens from individual
III-16 in Family 1 and one of the affected individuals from FamiliesFigure 1. Clinical, Histological, and
Genetic Aspects of FPLCA
(A) The pedigree of Family 1 showing auto-
somal-dominant inheritance; filled sym-
bols represent affected individuals.
(B) Clinical features of FPLCA. Skin on the
lower leg (individual III-16) appears dry,
scaly, and thickened with some hyperpig-
mentation.
(C) At higher magnification, there is accen-
tuation of the normal skin creases and
focal skin papules (lichenification).
(D) Histopathological features of FPLCA.
Skin biopsy of lesional skin shows pigmen-
tary incontinence (arrow) and amorphous
eosinophilic material (asterisk) in the
superficial papillary dermis (hematoxylin
and eosin) (scale bar represents 25 mm).
(E) These collections of material show
bright fluorescent labeling with thiofla-
vin-T (white arrows) (scale bar represents
25 mm).8
Figure 2. The Molecular Basis of FPLCA
Involves Heterozygous Missense Muta-
tions in the OSMR Gene
(A) DNA sequencing of OSMR. Sequencing
of genomic DNA in individuals with FPLCA
reveals heterozygous single-nucleotide
substitutions in OSMR c.2072T/C in Fam-
ily 1 and c.1853G/C in Families 2/3
(NM_003999). These convert an isoleucine
to threonine and a glycine to alanine,
designated p.I691T and p.G618A, respec-
tively.
(B) Structural model of OSMRb depicting
the functional domains and the sites of
the missense mutations. FNIII, fibronectin
type III-like domain; CBD, cytokine bind-
ing domain; Ig-like domain, immunoglobu-
lin-like domain. Amino acid (AA) numbers
of the 979 amino acid OSMRb protein are
shown on the left of the figure. The mis-
sense mutations p.I691T and p.G618A
are located within the extracellular FNIII
domains.
(C) Protein homology and amino acid iden-
tity indicate that amino acids p.I691 and
p.G618 are well conserved across several
species. The numbers at the start of the de-
picted sequences indicate the amino acid
numbers. Underlined amino acids are con-
served in all species shown here; p.I691
and p.G618 are highlighted in red.
(EGF)1, 5 mg/ml insulin, and 2 3 1011 M
liothyronine. Fresh mitomycin C-treated
NIH 3T3 feeder cells were added to pri-
mary keratinocytes twice a week. Early
passage keratinocytes were immortalized
with HPV16 (E6^E7), as described
previously.132 and 3, respectively, as well as normal control skin samples, with
RNeasy ﬁbrous tissue kits (QIAGEN) with subsequent cDNA syn-
thesis with Superscript II reverse transcriptase (Invitrogen).
Primers targeting near the 30-end of the cDNAwere used to amplify
IL-6-type cytokine receptors and the corresponding ligands
(primer details available on request).
Keratinocyte Isolation and Culture
Primary keratinocyte cultureswere isolated according to a standard
procedure.12 In brief, after mechanical dissociation, skin biopsy
fragments were immersed for 1 hr at 37C in trypsin-EDTA solu-
tion. The solution was then ﬁltered through a 100 mm pore cell
strainer (VWR), and then medium supplemented with 10% fetal
bovine serum (FBS) was added to neutralize the trypsin. Cells
were isolated with a centrifuge (5 min, 1000 rpm), and the pellet
was resuspended in normal keratinocyte medium. Finally, the cells
were seeded in T25 ﬂasks containing feeders. The keratinocytes
were maintained in DMEM:Ham’s F12 medium supplemented
with 10% FBS, 5 mg/ml transferrin, 0.4 mg/ml hydrocortisone,
1010 M cholera toxin, 10 ng/ml epidermal growth factorThCytokine Stimulation
Keratinocytes were seeded into 6-well plates and grown to conﬂu-
ency. Cells were maintained in normal keratinocyte media for
3–5 days after conﬂuency. Prior to cytokine stimulation, cells
were washed twice in phosphate-buffered saline (PBS) and incu-
bated in keratinocyte-deﬁned serum-free media (Invitrogen) for
either 2 or 24 hr. Cultures were then stimulated with the relevant
cytokine for 15 min prior to the preparation of lysates for
immunoblotting. Cytokines used in this study were recombinant
humanOSM, IL-6, and IL-31 (R&D Systems) (see Results). The con-
centrations of cytokines used were 10, 50, and 100 ng/ml for OSM
and 100 ng/ml for IL-6 and IL-31.
Immunoblotting
The cells were washed once with ice-cold PBS and lysed with
chilled RIPA buffer containing anti-proteases. Cell lysates were
resolved with 4%–12% NuPAGE Novex Bis-Tris Gels (Invitrogen).
The fractionated proteins were transferred to Hybond-ECL
nitrocellulose transfer membrane (Amersham Biosciences). The
membrane was blocked with 5% nonfat milk-TTBS for 2 hr ate American Journal of Human Genetics 82, 73–80, January 2008 75
room temperature and incubated overnight at 4C with the rele-
vant primary antibody. Antibody-antigen complexes were visual-
ized by enhanced chemiluminescence (Amersham Biosciences),
according to the manufacturer’s instructions. The optical density
of bands on the blot was calculated with Image J software. Primary
antibodies used were STAT1(42H3)(9175), STAT3(124H6)(9139),
STAT5(3H7)(9358), p44/42 MAP Kinase (Erk1/2)(9102), Akt
(9272), phospho-STAT1-Tyr701(9171), phospho-STAT3-Tyr705
(9131), phospho-STAT5-Tyr694(9351), phospho-p44/42 MAPK-
Thr202/Tyr204 (phosphor-Erk1/2; 9106), phospho-Akt-Ser473
(9271) (Cell Signaling Technology, Inc.). Secondary antibodies were
polyclonal goat anti-mouse immunoglobulins/HRP and polyclonal
swine anti-rabbit immunoglobulins/HRP (Dako Cytomation).
Results
Clinical and Histopathological Features of FPLCA
Sixteen subjects over four generations of the Brazilian ped-
igree were known to have FPLCA, with inheritance by au-
tosomal-dominant transmission (Figure 1A). In affected
individuals, symptoms typically started during childhood
with severe pruritus on the lower legs, leading to focal
skin licheniﬁcation (Figures 1B and 1C). Histopathology
of lesional skin showed pigmentary incontinence and
amorphous eosinophilic material in the papillary dermis
(Figure 1D), which stained positively for thioﬂavin-T, con-
sistent with amyloid deposition (Figure 1E). Clinico-path-
ological details of Family 2 (white British) and Family 3
(white South African) with autosomal-dominant FPLCA
have been reported previously.14,15
Identiﬁcation of OSMR as the FPLCA Gene
We performed linkage analysis in Family 1 with ﬁve micro-
satellite markers covering 5p13.1–q11.2 and conﬁrmed
this as the FPLCA locus. The disease-associated allele was
ﬂanked by D5S2021 and D5S407 with a maximum LOD
score of 4.8 for the microsatellite marker D5S418 (Table
1). The boundary of this interval on the short arm of
chromosome 5 was deﬁned by recombination between
Figure 3. Schematic Model of IL-6 Family Cyto-
kine Receptors
The IL-6 receptor comprises two gp130 and one IL-6R
molecules. There are two types of OSM receptors: type
I is composed of gp130 and LIFR, whereas type II
comprises gp130 and OSMRb. The IL-31 receptor is
composed of OSMRb and IL31RA. Each domain of
the receptors is colored similarly to the schematic
shown in Figure 2B.
D5S2021 and D5S418 in individual III-1,
whereas the boundary on the long arm of
chromosome 5 was deﬁned by recombination
between D5S1969 and D5S407 in individual
IV-2 (on the assumption that the penetrance
of the condition is complete). This ~18 cM in-
terval, which spans the centromere of chromosome 5, con-
tains more than 150 genes and in silico predicted genes.
This region spans the entire region of linkage on chromo-
some 5 previously reported,11 but widens the linkage inter-
val by ~2.8 cM beyond the boundary on the long arm.
Within the interval, we searched for genes that might
have pathophysiological relevance to skin itching. We
focused on the genes coding interleukin (IL)-6-type
receptors, given that overexpression of IL-31 in mice has
recently been shown to cause itchy dermatitis and that
oncostatin M (OSM) is a potent keratinocyte activator
involved in skin inﬂammation.16,17 Within our linked re-
gion, there are four IL-6 type receptors: IL6ST, LIFR,
IL31RA, and OSMR (which encode gp130, leukemia inhib-
itory factor receptor, IL-31 receptor A, and OSM-speciﬁc
receptor b, respectively). Two of these genes, OSMR and
LIFR, are also present within the Taiwanese linkage inter-
val.11 Sequencing of genomic DNA in Family 1 disclosed
a heterozygous point mutation in OSMR, c.2072T/C
(NM_003999) (Figure 2A), which was present in all the
affected individuals but not in any of the unaffected indi-
viduals. This mutation converts isoleucine to threonine at
amino acid 691 (p.I691T). Nomutations were found in any
of the other putative candidate genes. We then sequenced
the OSMR gene in Families 2 and 3 and found a heterozy-
gous missense mutation c.1853G/C (p.G618A) common
to the affected individuals in both pedigrees (Figure 2A).
Subsequent microsatellite analyses around the OSMR
gene indicated that Families 2 and 3 are likely to share a
common British ancestor (data not shown). Neither of
the missense mutations p.I691T or p.G618A was found in
screening 210 ethnically matched control chromosomes.
The mutations in the FPLCA families occur within the
extracellular ﬁbronectin type III-like (FNIII) domains of
OSMRb (Figure 2B), sites that have previously been shown
to be necessary for correct receptor function and signal
transduction.18 In addition, these particular mutated
amino acids are well conserved throughout various evolu-
tionary lineages (Figure 2C).76 The American Journal of Human Genetics 82, 73–80, January 2008
Expression and Function of OSMRb in FPLCA
OSMRb is a component of both the OSM type II recep-
tor19,20 and the IL-31 receptor (Figure 3).7 One of its
ligands, OSM, has known roles in cell proliferation, apo-
ptosis, differentiation, and inﬂammation,17,21 and in kera-
tinocytes, OSM has been shown to modulate expression of
several genes involved in innate immunity, angiogenesis,
adhesion, cell motility, tissue remodeling, cell-cycle regula-
tion, and transcription.21 In the OSM type II receptor,
OSMRb couples with gp130, which is the most common
receptor subunit of the IL-6-type cytokine receptors. OSM
also binds to the OSM type I receptor (LIFR and gp130),
although LIFR is barely expressed in keratinocytes.17 The
other ligand for OSMRb is IL-31, which has been shown
to induce severe pruritus in an animal model.16 In the
IL-31 receptor, OSMRb couples with the IL-31 receptor A
subunit. The IL-6 family of cytokine receptors typically
invoke signaling via the Jak/STAT, MAPK, and PI3K/Akt
pathways.19
To assess the functional consequences of the OSMR
mutations, we ﬁrst assessed mRNA expression levels of
the relevant IL-6 type cytokines and their receptors in
the affected subjects’ and control skin samples and cul-
tured keratinocytes by RT-PCR. All the IL-6-type cytokines
and their receptors examined were detected and expressed
at similar levels in all samples (not illustrated). Next,
FPLCA cultured keratinocytes (from Family 2) were stimu-
lated with OSM or IL-31, and the levels of phosphorylated
STATs, Erk1/2, and Akt were observed by western blotting.
Normal control keratinocytes responded to the OSM
strongly and, to a lesser extent, to IL-31, as recently docu-
mented.22 In FPLCA, however, the level of pSTATs, pErk,
and pAkt were reduced by ~65%–95% (assessed by optical
densitometry) after OSM stimulation, and no phosphory-
lation was observed after IL-31 stimulation (Figure 4, top
and middle). Response to OSM was dose dependent in
both FPLCA and control keratinocytes (Figure 4, top).
Stimulation with IL-6, which does not include OSMRb in
its receptor complex, did not result in altered phosphoryla-
tion in the FPLCA keratinocytes (Figure 4, bottom).
Discussion
This study has identiﬁed that mutations in the OSMRb
receptor underscore the molecular basis of FPLCA and
provide intriguing new insight into mechanisms of itch
and apoptosis in human skin. The OSMRbmissense muta-
tion p.G618A is located within the second FNIII domain,
and p.I691T occurs within the ﬁrst FNIII domain adjacent
to the transmembranous domain (Figure 2B). Previous
in vitro studies of FNIII deletions or single amino acid
substitutions in gp130 have disclosed key roles for these
domains in receptor dimerization for both gp130 homo-
dimers or gp130-LIFR heterodimers.18,23 Given that OSMRb
has a similar domain organization to gp130, we predict
that the amino acid substitutions p.G618A and p.I691TThin the FNIII regions of this receptor may interfere with
the normal receptor coupling between OSMRb and
gp130 as well as OSMRb with IL31RA. This then leads to
the decrease in signal activation by OSM and IL-31 in
FPLCA keratinocytes (Figure 4 and illustrated schemati-
cally in Figure 5).
OSMRb is widely expressed in many cells and tissues20
and a key question therefore is why do these mutations
Figure 4. Western Blotting of Phosphorylated (p)-STATs,
pErk1/2, and pAkt of Cultured Keratinocytes Stimulated with
OSM or IL-31
Phosphorylation of STATs, Erk1/2, and Akt was observed after stim-
ulation by OSM and IL-31 in normal human keratinocytes, but in
FPLCA keratinocytes (here illustrated for Family 2), there was re-
duced phosphorylation of STATs, Erk1/2, and Akt by OSM and no
activation by IL-31 (top and middle). The reduction of pSTAT3
was more clearly demonstrated at lower OSM concentrations
(top). Stimulation by IL-6 did not result in altered phosphorylation
in FPLCA keratinocytes (bottom).e American Journal of Human Genetics 82, 73–80, January 2008 77
Figure 5. Structural Representation of OSMR
Type II and IL-31 Receptor Signaling in Normal
and FPLCA Keratinocytes
Each domain of the receptors is colored similarly to
the schematic shown in Figure 2B. After binding of
OSM or IL-31 to these receptors, the FNIII domains
of both receptor subunits interact and signal trans-
duction occurs. The missense mutations seen in our
cases occur within the FNIII domains (black crosses),
regions critical for receptor dimerization and sub-
sequent signaling. Failure to form conformationally
functional receptor complexes in FPLCA leads to
reduced receptor signaling after stimulation with
either OSM or IL-31.result in what is predominantly a skin disease? Part of the
explanation for why heterozygous human missense muta-
tions result in FPLCA, however, could relate to lack of the
OSM-type I receptor in keratinocytes which, when present
in other tissues, may compensate for any dysfunctional
OSM-type II receptor. Another possibility might relate to
recent ﬁndings of coexpression of OSMRb and IL-31RA
in skin cells (speciﬁc cell types yet to be determined) as
well as in nociceptive neurons in dorsal root ganglia that
project into the dermis in skin.24,25 Thus, it is plausible
that the clinicopathological features of FPLCA may only
manifest at sites where both types of receptor that contain
OSMRb are expressed.
The precise cellular mechanisms through which the
OSMRbmutations result in reduced OSM and IL-31 signal-
ing, such as impaired signaling via a mutant receptor com-
plex or premature degradation of the mutant OSMRb lead-
ing to reduced amounts of OSMRb available to form dimers
with gp130 or IL-31R upon ligand activation, are not yet
known. Nevertheless, our new data are able to provide an
explanation for the histological ﬁnding of increased kerati-
nocyte apoptosis in FPLCA.We found decreased activation
of Jak/STAT, Erk1/2, and PI3K/Akt signaling, pathways that
have been reported to have antiapoptotic effects in several
tumor cell lines.26,27 Keratinocytes with mutated OSMRb,
therefore, may be more susceptible to apoptosis, resulting
in cell death and accumulation of degenerate keratinous
material in the superﬁcial dermis. It is not currently known
whether similar apoptosis occurs in nociceptive neurons in
FPLCA, although degenerative changes in some nerves
in the dermis have been noted on transmission electron
microscopy.5
Howmutations in OSMRb lead to increased skin itching,
however, requires further study. Our current data show de-
creased signaling in FPLCA keratinocytes after stimulation
with OSM or IL-31, in contrast to other reports indicating
that itchy dermatitis inmice results from overexpression of78 The American Journal of Human Genetics 82, 73–80, January 200IL-31.16 The role of the other OSMRb-associated ligand,
OSM, in nociceptive neurons has not been fully eluci-
dated, although it has been suggested that OSM may sus-
tain pain during inﬂammation.28 Precisely how OSMRb
gene mutations might affect the function of nociceptive
neurons, however, is not clear, but if a link can be shown,
this mechanism might have relevance to explaining the
concept of neurological itching in skin (‘‘neurodermati-
tis’’), which is often a clinical consideration in many pa-
tients with chronic skin itching. With regard to FPLCA,
therefore, this disorder could represent the ﬁrst example
of a true neurodermatitis rather than a primary disorder
of keratinocytes.
Demonstration of pathogenic mutations in OSMRb in
FPLCA now provides an opportunity to explore whether
abnormalities in signaling via this cytokine receptor are
also present in sporadic cases of PLCA as well as perhaps
in acquired itchy dermatoses with lichenoid patterns of
skin inﬂammation, such as lichen planus or graft-versus-
host disease. Moreover, given the association of PLCA
with various connective tissue and autoimmune patholo-
gies,2 our ﬁndings may also help focus assessment of spe-
ciﬁc IL-6 signaling responses in these common disorders.
Such investigations may lead to new therapeutic targets
for these conditions as well as for the most common of
all dermatological symptoms, itch.
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